1. Home
  2. In Vitro Diagnostics
  3. Infectious Diseases
  4. HBe Ag&Ab

HBe Ag&Ab

Enzyme ImmunoAssay (ELISA) for the determination of Hepatitis B Virus "e" Antigen and Antibody in human plasma and sera.

Regulatery Status: CE
Catalog No Size
Product Catalog No: HBE Pack Size: 96 Wells

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Summary

Hepatitis B “e” Antigen or HBeAg is known to be intimately associated with Hepatitis B Virus or HBV replication and the presence of infectious Dane particles in the blood.

Recently, it has been found that HBeAg is a product of proteolytic degradation of Hepatitis B core Antigen or HBcAg, occurring in hepatocites, whose expression is under the control of the precore region of HBV genome.

If HBeAg is considered a specific marker of infectivity, the presence of anti HBeAg antibodies in blood is recognised to be a clinical sign of recovery from infection to convalescence.

The determination of these two analytes in samples from HBV patients has become important for the classification of the phase of illness and as a prognostic value in the follow up of infected patients.

Test Principle

HBeAg, if present in the sample, is captured by a specific monoclonal antibody, in the 1st incubation.

In the 2nd incubation, after washing, a tracer, composed of a mix of two specific anti HBeAg monoclonal antibodies, labeled with peroxidase (HRP), is added to the microplate and binds to the captured HBeAg. The concentration of the bound enzyme on the solid phase is proportional to the amount of HBeAg in the sample and its activity is detected by adding the chromogen/substrate in the 3rd incubation.

The presence of HBeAg in the sample is determined by means of a cutoff value that allows for the semiquantitative detection of the antigen.

Order Enquiry

    Order Enquiry Form

    References
    1. Engvall E. and Perlmann P.. J. Immunochemistry, 8, 871-874, 1971
    2. Engvall E. and Perlmann P.. J.Immunol. 109, 129-135, 1971
    3. Remington J.S. and Klein J.O.. In “Infectious diseases of the fetus and newborn infant”. Sanders, Philadelphia, London, Toronto.
    4. Volk W.A.. In “Essential of Medical Microbiology”. 2nd ed. pp 729, G.B.Lippincott Company, Philadelphia, New York, S.Josè, Toronto.
    5. Snydman D.R., Bryan J.A. and Dixon R.E.. Ann.Int.Med., 83, pp 838, 1975.
    6. Barker L.F., Gerety R.J., Lorenz D.E.. Viral Hepatitis. 581-587, 1978.
    7. Cossart Y.. Brit.Med.Bull.. 28, pp 156, 1972
    8. Lander J.J., Alter H. and Purcell R.. J.Immunol.. 106, pp 1066, 1971
    9. Mushawar I.K., Dienstag J.L., Polesky H.F. et al.. Ann.J.Clin.Pathol.. 76, pp 773, 1981.
    10. Ling C.M., Mushawar I.K. et al.. Infection and Immunity, 24: 235, 1979.
    Documents
    Enquiry